Vaxcyte (PCVX) Interest Expenses (2019 - 2022)

Vaxcyte (PCVX) has reported Interest Expenses for 8 consecutive years, with $3.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest Expenses rose 20.2% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at -$1.6 million (up 69.65% YoY), while the FY2025 annual figure was $645.3 million, up 44.66% from the prior year.
• Interest Expenses declined to $3.7 million in Q1 2026 per PCVX's latest filing, from $130.4 million in the prior quarter.
• Across five years, Interest Expenses topped out at $363.1 million in Q1 2024 and bottomed at -$8.4 million in Q4 2024.
• Historically, Interest Expenses has averaged $106.6 million across 5 years, with a median of $78.8 million in 2022.
• On a YoY basis, Interest Expenses climbed as much as 3165.83% in 2025 and fell as far as 99.15% in 2025.
• Vaxcyte's Interest Expenses stood at $74.1 million in 2022, then soared by 235.74% to $248.9 million in 2023, then tumbled by 103.38% to -$8.4 million in 2024, then surged by 1650.69% to $130.4 million in 2025, then plunged by 97.16% to $3.7 million in 2026.
• Business Quant data shows PCVX's Interest Expenses at $3.7 million in Q1 2026, $130.4 million in Q4 2025, and $118.0 million in Q3 2025.